{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:03Z","timestamp":1791316743616,"version":"4.3.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373715"],"award-info":[{"award-number":["82373715"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02644-1","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:01:40Z","timestamp":1775606500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1\/2-Cyclin D1\/CDK4\/6 axis"],"prefix":"10.1038","volume":"11","author":[{"given":"Ting","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenliang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziping","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-4717","authenticated-orcid":false,"given":"Wenchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-2547","authenticated-orcid":false,"given":"Qingsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2644_CR1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","volume":"21","author":"T Sen","year":"2024","unstructured":"Sen, T. et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat. Rev. Clin. Oncol. 21, 610\u2013627 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2644_CR2","first-page":"620","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi, Z. et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J. Clin. 73, 620\u2013652 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2644_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin, C. M. et al. Small-cell lung cancer. Nat. Rev. Dis. Primers 7, 3 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2644_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/cancers16020255","volume":"16","author":"F Meriggi","year":"2024","unstructured":"Meriggi, F. Second-line treatment options for small-cell lung cancer: a light at the end of the tunnel. Cancers 16, 255 (2024).","journal-title":"Cancers"},{"key":"2644_CR5","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41591-024-03255-5","volume":"30","author":"N Li","year":"2024","unstructured":"Li, N. & Wang, S. Y. Navigating treatment combinations in small-cell lung cancer. Nat. Med. 30, 2731\u20132732 (2024).","journal-title":"Nat. Med."},{"key":"2644_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J. Thorac. Oncol. 18, 31\u201346 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2644_CR7","doi-asserted-by":"publisher","first-page":"117147","DOI":"10.1016\/j.biopha.2024.117147","volume":"178","author":"M Sun","year":"2024","unstructured":"Sun, M. et al. Posttranslational modifications of E2F family members in the physiological state and in cancer: roles, mechanisms and therapeutic targets. Biomed. Pharmacother. 178, 117147 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"2644_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.326","volume":"5","author":"P Meng","year":"2014","unstructured":"Meng, P. & Ghosh, R. Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?. Cell Death Dis. 5, e1360 (2014).","journal-title":"Cell Death Dis."},{"key":"2644_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)81254-4","volume":"85","author":"L Yamasaki","year":"1996","unstructured":"Yamasaki, L. et al. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85, 537\u2013548 (1996).","journal-title":"Cell"},{"key":"2644_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s12885-023-10865-8","volume":"23","author":"J Li","year":"2023","unstructured":"Li, J. et al. Prognostic role of E2F1 gene expression in human cancer: a meta-analysis. BMC Cancer 23, 509 (2023).","journal-title":"BMC Cancer"},{"key":"2644_CR11","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/sj.onc.1204242","volume":"20","author":"B Eymin","year":"2001","unstructured":"Eymin, B. et al. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 20, 1678\u20131687 (2001).","journal-title":"Oncogene"},{"key":"2644_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-276","volume":"14","author":"Z Li","year":"2014","unstructured":"Li, Z. et al. Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer 14, 276 (2014).","journal-title":"BMC Cancer"},{"key":"2644_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3701-y","volume":"17","author":"T Wang","year":"2017","unstructured":"Wang, T. et al. Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer. BMC Cancer 17, 719 (2017).","journal-title":"BMC Cancer"},{"key":"2644_CR14","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1158\/0008-5472.CAN-08-0121","volume":"68","author":"Y Ma","year":"2008","unstructured":"Ma, Y. et al. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res. 68, 6292\u20136299 (2008).","journal-title":"Cancer Res."},{"key":"2644_CR15","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1021\/jacs.1c03852","volume":"143","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. TF-PROTACs enable targeted degradation of transcription factors. J. Am. Chem. Soc. 143, 8902\u20138910 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"2644_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.bbrc.2003.09.124","volume":"310","author":"JD Ahn","year":"2003","unstructured":"Ahn, J. D. et al. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem. Biophys. Res. Commun. 310, 1048\u20131053 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2644_CR17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0140-6736(99)09405-2","volume":"354","author":"MJ Mann","year":"1999","unstructured":"Mann, M. J. et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354, 1493\u20131498 (1999).","journal-title":"Lancet"},{"key":"2644_CR18","doi-asserted-by":"publisher","first-page":"33249","DOI":"10.18632\/oncotarget.26064","volume":"9","author":"T Shaik","year":"2018","unstructured":"Shaik, T. et al. Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget 9, 33249\u201333257 (2018).","journal-title":"Oncotarget"},{"key":"2644_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4161\/cbt.25184","volume":"14","author":"X Xie","year":"2013","unstructured":"Xie, X. et al. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer. Cancer Biol. Ther. 14, 742\u2013751 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"2644_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ijpharm.2017.02.020","volume":"525","author":"S Bochicchio","year":"2017","unstructured":"Bochicchio, S. et al. In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. Int. J. Pharm. 525, 377\u2013387 (2017).","journal-title":"Int. J. Pharm."},{"key":"2644_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000113491","volume":"72","author":"L Guo","year":"2007","unstructured":"Guo, L., Guo, Y. & Xiao, S. Expression of tyrosine kinase Etk\/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology 72, 410\u2013416 (2007).","journal-title":"Oncology"},{"key":"2644_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/0008-5472.CAN-14-1340","volume":"75","author":"JL Fox","year":"2015","unstructured":"Fox, J. L. & Storey, A. BMX negatively regulates BAK function, thereby increasing apoptotic resistance to chemotherapeutic drugs. Cancer Res. 75, 1345\u20131355 (2015).","journal-title":"Cancer Res."},{"key":"2644_CR23","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/0008-5472.CAN-17-3615","volume":"78","author":"S Chen","year":"2018","unstructured":"Chen, S. et al. BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. Cancer Res. 78, 5203\u20135215 (2018).","journal-title":"Cancer Res."},{"key":"2644_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1593\/neo.131376","volume":"16","author":"DS Potter","year":"2014","unstructured":"Potter, D. S. et al. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. Neoplasia 16, 147\u2013157 (2014).","journal-title":"Neoplasia"},{"key":"2644_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0847-5","volume":"19","author":"XF Xu","year":"2019","unstructured":"Xu, X. F. et al. BMX-ARHGAP fusion protein maintains the tumorigenicity of gastric cancer stem cells by activating the JAK\/STAT3 signaling pathway. Cancer Cell Int. 19, 133 (2019).","journal-title":"Cancer Cell Int."},{"key":"2644_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12282-019-01024-8","volume":"27","author":"K Li","year":"2020","unstructured":"Li, K. et al. BMX activates Wnt\/beta-catenin signaling pathway to promote cell proliferation and migration in breast cancer. Breast Cancer 27, 363\u2013371 (2020).","journal-title":"Breast Cancer"},{"key":"2644_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1172\/JCI91893","volume":"128","author":"JG van Oosterwijk","year":"2018","unstructured":"van Oosterwijk, J. G. et al. Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J. Clin. Invest. 128, 369\u2013380 (2018).","journal-title":"J. Clin. Invest."},{"key":"2644_CR28","doi-asserted-by":"publisher","first-page":"11959","DOI":"10.1007\/s13277-016-5048-4","volume":"37","author":"J Peng","year":"2016","unstructured":"Peng, J. et al. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K\/BMX\/STAT3 signaling pathway. Tumour Biol. 37, 11959\u201311971 (2016).","journal-title":"Tumour Biol."},{"key":"2644_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.yexmp.2010.02.003","volume":"88","author":"L Guo","year":"2010","unstructured":"Guo, L. et al. Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells. Exp. Mol. Pathol. 88, 401\u2013406 (2010).","journal-title":"Exp. Mol. Pathol."},{"key":"2644_CR30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/1078-0432.CCR-17-1475","volume":"24","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. Etk Interaction with PFKFB4 modulates chemoresistance of small-cell lung cancer by regulating autophagy. Clin. Cancer Res. 24, 950\u2013962 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2644_CR31","first-page":"628","volume":"7","author":"T Wei","year":"2017","unstructured":"Wei, T. et al. miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk\/BMX. Am. J. Cancer Res. 7, 628\u2013646 (2017).","journal-title":"Am. J. Cancer Res."},{"key":"2644_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41388-019-0984-2","volume":"39","author":"F Zeng","year":"2020","unstructured":"Zeng, F. et al. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene 39, 293\u2013307 (2020).","journal-title":"Oncogene"},{"key":"2644_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1535-7163.MCT-15-0885","volume":"15","author":"DS Potter","year":"2016","unstructured":"Potter, D. S. et al. Inhibition of PI3K\/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC. Mol. Cancer Ther. 15, 1248\u20131260 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2644_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0092-8674(94)90522-3","volume":"78","author":"R Fagan","year":"1994","unstructured":"Fagan, R., Flint, K. J. & Jones, N. Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19 kDa protein. Cell 78, 799\u2013811 (1994).","journal-title":"Cell"},{"key":"2644_CR35","doi-asserted-by":"crossref","unstructured":"Dubrez, L. Regulation of E2F1 transcription factor by ubiquitin conjugation. Int. J. Mol. Sci. 18, 2188 (2017).","DOI":"10.3390\/ijms18102188"},{"key":"2644_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1349-7006.2006.00244.x","volume":"97","author":"S Torii","year":"2006","unstructured":"Torii, S. et al. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 97, 697\u2013702 (2006).","journal-title":"Cancer Sci."},{"key":"2644_CR37","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano, A. et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist. Updat. 76, 101103 (2024).","journal-title":"Drug Resist. Updat."},{"key":"2644_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/2321-3868.135483","volume":"2","author":"L Qiu","year":"2014","unstructured":"Qiu, L. et al. Current understanding of tyrosine kinase BMX in inflammation and its inhibitors. Burns Trauma 2, 121\u2013124 (2014).","journal-title":"Burns Trauma"},{"key":"2644_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/08830185.2012.663838","volume":"31","author":"B Cenni","year":"2012","unstructured":"Cenni, B., Gutmann, S. & Gottar-Guillier, M. BMX and its role in inflammation, cardiovascular disease, and cancer. Int. Rev. Immunol. 31, 166\u2013173 (2012).","journal-title":"Int. Rev. Immunol."},{"key":"2644_CR40","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1073\/pnas.0511292103","volume":"103","author":"JS Melnick","year":"2006","unstructured":"Melnick, J. S. et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl. Acad. Sci. USA 103, 3153\u20133158 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2644_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1365-2141.2001.02905.x","volume":"114","author":"T Futatani","year":"2001","unstructured":"Futatani, T. et al. Bruton\u2019s tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br. J. Haematol. 114, 141\u2013149 (2001).","journal-title":"Br. J. Haematol."},{"key":"2644_CR42","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/17512433.2022.2106968","volume":"15","author":"D Jiang","year":"2022","unstructured":"Jiang, D. et al. Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials. Expert Rev. Clin. Pharmacol. 15, 987\u2013996 (2022).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2644_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71040-8","volume":"10","author":"K Salokas","year":"2020","unstructured":"Salokas, K., Weldatsadik, R. G. & Varjosalo, M. Human transcription factor and protein kinase gene fusions in human cancer. Sci. Rep. 10, 14169 (2020).","journal-title":"Sci. Rep."},{"key":"2644_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","volume":"66","author":"R Roskoski","year":"2012","unstructured":"Roskoski, R. Jr. ERK1\/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 66, 105\u2013143 (2012).","journal-title":"Pharmacol. Res."},{"key":"2644_CR45","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel, S., Bergholz, J. S. & Zhao, J. J. Targeting CDK4 and CDK6 in cancer. Nat. Rev. Cancer 22, 356\u2013372 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2644_CR46","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/01.CIR.96.6.1729","volume":"96","author":"N Ekman","year":"1997","unstructured":"Ekman, N. et al. Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation 96, 1729\u20131732 (1997).","journal-title":"Circulation"},{"key":"2644_CR47","doi-asserted-by":"publisher","first-page":"32689","DOI":"10.1074\/jbc.M703412200","volume":"282","author":"X Jiang","year":"2007","unstructured":"Jiang, X. et al. Activation of nonreceptor tyrosine kinase Bmx\/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J. Biol. Chem. 282, 32689\u201332698 (2007).","journal-title":"J. Biol. Chem."},{"key":"2644_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molcel.2010.06.006","volume":"39","author":"H Kontaki","year":"2010","unstructured":"Kontaki, H. & Talianidis, I. Lysine methylation regulates E2F1-induced cell death. Mol. Cell 39, 152\u2013160 (2010).","journal-title":"Mol. Cell"},{"key":"2644_CR49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41392-022-01013-y","volume":"7","author":"M Yuan","year":"2022","unstructured":"Yuan, M. et al. Signal pathways and precision therapy of small-cell lung cancer. Signal Transduct. Target. Ther. 7, 187 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2644_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jcc.23136","volume":"34","author":"X Ouyang","year":"2013","unstructured":"Ouyang, X. et al. CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. J. Comput. Chem. 34, 326\u2013336 (2013).","journal-title":"J. Comput. Chem."},{"key":"2644_CR51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/09537104.2020.1719056","volume":"31","author":"BM Mohammed","year":"2020","unstructured":"Mohammed, B. M., Monroe, D. M. & Gailani, D. Mouse models of hemostasis. Platelets 31, 417\u2013422 (2020).","journal-title":"Platelets"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02644-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:01:42Z","timestamp":1775606502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02644-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2644"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02644-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}